Board of Directors

Rajiv Gupta has served as Chairman of our Board since August 2010. Mr. Gupta is a Senior Advisor to New Mountain Capital, LLC. Previously, Mr. Gupta served as Chairman of Delphi Automotive PLC, from April 2015 to November 2017, when it separated into two companies. For ten years, Mr. Gupta served as Chairman and Chief Executive Officer of Rohm and Haas Company, when it was acquired by Dow Chemical. Mr. Gupta previously held various other positions at Rohm and Haas, which he joined in 1971, including serving as Vice Chairman, Director of the Electronic Materials business and Vice President and Regional Director of the Asia Pacific Region. Mr. Gupta currently serves as a director of Arconic, Inc. and Aptiv PLC. Mr. Gupta holds a master’s degree in operations research from Cornell University, an MBA in finance from Drexel University and a bachelor’s degree in mechanical engineering from the Indian Institute of Technology. Mr. Gupta’s prior long-term, senior level experience at a major global chemical company, including serving as Chairman and Chief Executive Officer, and his expertise in financial accounting, international business transactions and strategy, make him a valuable member of our Board.

Michael Stubblefield is our President and CEO, a position he has held since May 2014. Prior to assuming his current position, Mr. Stubblefield served as a Senior Expert for Chemicals Practice of McKinsey & Company from 2013 to 2014. Prior to this role, Mr. Stubblefield held a variety of roles at Celanese Corporation from 1994 to 2012, including Vice President and General Manager, Advanced Engineered Materials and Chief Marketing Officer. Mr. Stubblefield earned a bachelor’s degree in chemical engineering from the University of Utah, as well as an MBA from Texas A&M University-Corpus Christi.

Juan Andres has served on our Board since September 2019 and is a member of the Audit & Finance Committee. Mr. Andres is the Chief Technology Operations and Quality Officer for Moderna, Inc., a position he has held since August 2017. Prior to that role, Mr. Andres served in several leadership positions at Novartis, most recently serving as the Global Head of Technical Operations (Manufacturing and Supply Chain). In previous roles at Novartis, Mr. Andres served as Group Novartis Quality Head, Global Head of Technical Research and Development, and Global Pharmaceuticals Operations Head. Mr. Andres also spent 18 years at Eli Lilly Company, serving in a variety of leadership positions. Mr. Andres serves on the board of directors of Ring Therapeutics. Mr. Andres holds a master’s degree in pharmacy from Alcala de Henares University in Madrid, Spain, and has completed an advanced development program at the London Business School. Mr. Andres’ extensive experience in pharmaceutical manufacturing, supply chain and technical research, along with his independence, makes him a valuable member of our Board.

Dr. John Carethers has served on our Board since July 2021. Dr. Carethers is the John G. Searle Professor and Chair of the Department of Internal Medicine at the University of Michigan Medical School based in Ann Arbor, Michigan, a position he has held since 2009. In addition, he was named the C. Richard Boland Distinguished University Professor in 2017 and is also a Professor of Human Genetics. Dr. Carethers was elected as a member of the National Academy of Medicine in 2012 and became an elected fellow of the Royal College of Physicians in 2021. Previously, Dr. Carethers served in a variety of roles at the University of California San Diego, including as a Professor of Medicine and Chief of the Division of Gastroenterology. Dr. Carethers holds an M.D., as well as a Bachelor of Science in biological sciences from Wayne State University, completing his internship and residency in internal medicine at Massachusetts General Hospital and his fellowship in gastroenterology at the University of Michigan. Dr. Carether’s senior leadership experience at a medical college and extensive research experience in familial cancer syndromes, including tumor genetics, DNA mismatch repair, and colorectal cancer disparities, along with his independence, make him a valuable member of our Board.

Matthew Holt has served on our Board since August 2010. Mr. Holt is a Managing Director of New Mountain Capital, LLC. He serves as the Deputy Head of Private Equity at New Mountain, focusing on growth buyouts across a range of industries including healthcare products, health technology, materials and infrastructure. He previously worked in the Mergers and Acquisitions Group at Lehman Brothers. He currently serves as Lead Director or Chairman of CIOX Health, Convey Health Solutions, Inc., Cytel, Equian LLC, Remedy Partners, Revint Solutions, Signify Health, and Zep, Inc. He also serves as a board director of Topix Pharmaceuticals, Gelest, TRC Companies. Mr. Holt earned an A.B. in English and American Literature and Language from Harvard College. Mr. Holt’s senior management experience as a Managing Director of New Mountain Capital, board and advisory experience with other companies in the healthcare industry and his extensive experience in the areas of finance, strategy, international business transactions and mergers and acquisitions, make him a valuable member of our Board.

Lan Kang has served on our Board since May 2021. Ms. Kang is Managing Director at CBC Group, a healthcare-focused private equity investment firm based in Shanghai, China, a position she has held since December 2020, and serves on the board of directors of Everest Medicines. Previously, Ms. Kang served as a Senior Advisor to Shanghai Henlius Biotech, a global clinical-stage biopharma company. Ms. Kang also served in a variety of roles at Fosun International, a Hong Kong stock exchange listed, consumer-focused multinational company, including Executive Board Director, Chief Human Resources Officer and Head of the Fosun Insurance Group. Prior to Fosun, she was a Senior Client Partner at Korn Ferry International and was an Engagement Manager at McKinsey & Company. Ms. Kang holds an MBA in healthcare management from The Wharton School of the University of Pennsylvania, a master’s degree in chemistry from Tulane University and a bachelor’s degree in biological science and technology from Zhejiang University in Hangzhou, China. Ms. Kang’s extensive experience in healthcare and biopharma, along with her independence, makes her a valuable member of our Board.

Jonathan Peacock is our Lead Independent Director and has served on our Board since April 2017 and is Chair of the Audit & Finance Committee and a member of the Nominating & Governance Committee. Mr. Peacock currently serves as Chairman of Bellerophon Therapeutics, Inc. and as a director of UCB SA/NV. Previously, Mr. Peacock served as Chief Executive Officer of Bellerophon Therapeutics, Inc., and also served as Chairman of the Board during that time. Prior to that, Mr. Peacock served as the Chief Financial Officer of Amgen Inc. Mr. Peacock has also held the role of Chief Financial and Administrative Officer of the pharmaceutical division of Novartis. In former roles, Mr. Peacock served as a partner at McKinsey & Company, and at PricewaterhouseCoopers (PwC). Mr. Peacock earned an M.A. in economics from the University of St. Andrews in Scotland. Mr. Peacock’s prior senior leadership experience, including as Chief Executive Officer and Chief Financial Officer, current and past experience as a board member at other companies and his expertise in finance, strategy and financial accounting, including qualification as an audit committee financial expert, along with his independence, make him a valuable member of our Board.

Dr. Michael Severino has served on our Board since April 2020 and is a member of the Audit & Finance Committee. Dr. Severino currently serves as Vice Chairman and President of AbbVie Inc. Prior to this role, Dr. Severino served as AbbVie’s Executive Vice President, Research & Development, and its Chief Scientific Officer. He also spent 10 years at Amgen, Inc., serving in a variety of leadership positions, including Senior Vice President Global Development, and Chief Medical Officer. Dr. Severino also serves on the board of directors for the Field Museum in Chicago, Illinois. He earned an M.D. from Johns Hopkins University, completing his residency and fellowship training at Massachusetts General Hospital and Harvard Medical School, as well as a bachelor’s degree in biochemistry from the University of Maryland. Dr. Severino’s extensive experience in research and development and corporate strategy for leading companies focused on developing life-saving therapies for patients, along with his independence, makes him a valuable member of our board.

Christi Shaw has served on our Board since November 2018 and is a member of the Compensation & Human Resources Committee and the Nominating & Governance Committee. Ms. Shaw currently serves as Chief Executive Officer of Kite, the cell therapy company of Gilead. Prior to this role, Ms. Shaw was Senior Vice President of Eli Lilly Company, and President of Lilly Bio-Medicines, the business within Eli Lilly Company that comprises neuroscience and immunology. In former roles, Ms. Shaw held several leadership roles, including U.S. Country Head and President of Novartis Pharmaceutical Corporation and North American Region Head of Novartis Oncology. Previously, Ms. Shaw has also held several leadership positions at Johnson & Johnson, Inc. Ms. Shaw serves as an executive board member of the Biotechnology Innovation Organization and is the co-founder of the More Moments More Memories Foundation to assist people with cancer and their caregivers. Ms. Shaw holds an MBA from the University of Wisconsin and a BBA in marketing from Iowa State University. Ms. Shaw’s extensive senior leadership experience within the healthcare industry and service as a Board Member of a large trade organization, along with her independence, make her a valuable member of our Board.

Greg Summe has served on our Board since May 2020 and is Chair of the Nominating & Governance Committee and a member of the Compensation & Human Resources Committee. Mr. Summe currently serves as Co-Chairman for NextGen Acquisition Corporation and as Managing Partner of Glen Capital Partners, a Boston-based hedge fund, which he founded in 2014. He also serves on the board of directors of the State Street Corporation and NXP Semiconductors NV. Prior to this, he was Managing Director and Vice Chairman of Global Buyout at The Carlyle Group. He also spent 11 years as the Chairman and Chief Executive Officer of PerkinElmer. Before PerkinElmer, Mr. Summe was with AlliedSignal, now Honeywell International, serving as the President of General Aviation Avionics, President of the Aerospace Engines Group and President of the Automotive Products Group. Mr. Summe holds an MBA with distinction from The Wharton School of the University of Pennsylvania, a master’s degree in electrical engineering from University of Cincinnati and a bachelor’s degree in electrical engineering from University of Kentucky. He is in the Engineering Hall of Distinction at the University of Kentucky. Mr. Summe’s extensive leadership experience in key industries, including life sciences and applied materials, along with his independence, make him a valuable member of our Board.